BTAI - Earnings call transcript Q3 2020 | BioXcel Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the BioXcel Therapeutics Third Quarter 2020 Financial Results Conference Call. At this time all participants are in a listen-only mode.

Just to remind everyone certain matters discussed in today's conference call and our answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties relating to future events and or the future financial performance of the company. Actual results could differ materially from those anticipated in the forward-looking statements. The risk factors that may affect results are detailed in the company's most recent public filings with the U.S. can including -- report quarterly www.sec.gov. excuse September XXXX, Commission, for Form period Exchange its XX, quarter on the me, which and its or on quarterly XX-Q ended website Securities www.bioxceltherapeutics.com found on be for the question follow formal session presentation. will answer and A the

As It's CEO. my Please ahead. call pleasure to to recorded. this a over Mehta, being turn Vimal reminder, is now the call go

Vimal Mehta

BioXcel Good morning, of conference everyone. And financial for highlights you business our discuss everyone's XXXX. time quarter operator. thank call and joining for to attention. you, Therapeutics appreciate third and results Thank the We

Frank Joining Will Chief Robert and Senior today Kane, me Chief Scientific are Vice Officer; Officer; Risinger, Clinical Development. President Commercial Chief Officer; Vince O'Neill, Financial Benabou, call Yocca, on Chief Reina Medical Officer; Richard the Officer; of Steinhart, Development Chief

uncertainty pandemic clinical, drive, world, our for their create As commitment, proud significant the on am to make of and in front. COVID-XX very and we corporate progress team the collaboration continues I commercial as the

During importantly, our the will we protecting to and community. serving our BXCLXXX. of health today's most challenging candidate clinical calls by begin time, lead remain discussing dedicated this I

acute is the our the we on we quarter had submission of the meeting patients to to data have and that from As disorders, our and in submit pivotal treatment to top-line calm a of dissolving reminder, bipolar trials month, first film withdrawal in orally the treatment initiated symptoms. excessive the demonstrated X of discussion, agitation a schizophrenia opiate and FDA. and XXX a outcome without rolling sedation. with which agitation ability across thin FDA we Last complete pre-NDA and X year, meta positive announced sublingual of quickly the for patients neuropsychiatric media BXCLXXX's proprietary XXXX. Based of numerous Earlier on track are with for disorders, this serenity application our safely

commercial our and by teams FDA. core build upon team framework order leadership to corporate our expand of to the in potential commercial approval medical continue We launch the BXCLXXX and for the needed

our buccally Turning of in XXX bioequivalence gum. ease a bioequivalence and program, giant the submission. or To this further assess healthy BXCLXXX sublingually buccal meaning recently a administer or step crossover to the exploring completed this end, lip neuroscience acute the film sublingually establishing delivery represent franchise. between term sublingual candidate trial to supported our clinical from the bioequivalence leading volunteers follow-on this administered lower study long forward indications. This development XXX treatment patient of that either The with in and schizophrenia following ability our NDA data well the bipolar of products. be on and for buccally the our we of included our or a will are of multiple agitation XXX, we way vision in approval new FDA of would in of shows An disorders thin in

of the treatment suffering agitation purpose to the and dementia Moving trial study study the tolerable our doses the XBX to of with elderly Phase effective in patient in for identify most patients from this acute population. the TRANQUILITY

additional review report this needed findings either later quarter will and dose from or to results child We topline proceed the if an the cohort.

box know, current warning. and treatments you treatments with FDA-approved off-label As are dementia there associated agitation of no black have

As dementia the facilitate will this in indication, a Track BXCLXXX development help designation which we for have the of FDA. Fast reminder, with received

results and the opiate of resulting study BXCLXXX rise, for to mitigate quarter XBX by trial the of in to release decreasing study, recovery XXXX. this the to and debilitating we of of withdrawal individual's symptoms, the the on first has hyperarousal on treatment period is rate Turning cases track abuse withdrawal well reducing a symptoms Phase an ability offline opioid we the With progressing believe potential relapse. BXCLXXX easier in remain our the report

received FDA IND indication can underlying the itself delirium, Delirium we our diseases, multiple be ICUs, this caused addition, including settings, candidate. for In and surgical rooms. and with by clearance potential application wards, of for emergency recently presents a for fifth including agitation acute associated medical, and multiple medical treatment COVID-XX across

We a ICU delirium, agitation COVID-XX X trial the are initiate with preparing to months. in coming with including Phase patients in patients associated

a episodes see, bipolar disorders, committed agitation we to in remain of schizophrenia of dementia. treatment you the as and can acute potential exploring full As BXCLXXX and for

We as for We delirium. the in and agitation whom not truly our treatment chronic suffering patients. symptoms, be millions XXX agitation, plan dementia are treatment for advancing programs in evaluate therapy options. can treatment We individuals agitation of of for any do many believe have a opioid from associated withdrawal effective to XXX with subchronic managing viable

immune along SITC. posters additional enhance from two sides. the believe combination of immune-oncology cancer look to with Anderson the conversation from Now, both We treatments stimulate in Annual ongoing the to MD BXCLXXX's XXX This our ability and trials and our collaborator, Anderson Phase innate with to efficacy designed lead combination both anti-tumor like mechanism both is orally to MD trial in innate of I systemic presented with All augment most data activity and BXCLXXX trial would candidate to and hot forward on cold supporting initial we advanced of in and continuing tumors, basket we action to responses Meeting ongoing Cancer and prostate system the turn clinical immunity Phase at acquired advance of checkpoint cancer X the in In development activator. or BXCLXXX to and the BXCLXXX inhibitors. we one available Immunotherapy XBX observe week KEYTRUDA of Society in encouraging innate both safety an immunity. provide all, advanced efficacy plans

achieve into I our million cash that, and in Richard commercial we call providing these a a $XXX see, well regulatory, Richard. approximately over operational can CFO, increased With milestone. our like public clinical, on July, execute all activities, to upcoming To to Steinhart, offering would proceeds you the to gross turn in fronts. raise continued to of As we have BioXcel support runway XXXX

Richard Steinhart

Thanks, a reported XXXX, again, Vimal. a BTAI period joining $XX.X loss for quarter of of net to same for million us compared for net loss XXXX. all you this of thank third Once the the in million morning. $X

third Personnel and the date trials. generally costs results same million X The and were third stock. research as personnel clinical with $X.X Development market fees grant well higher development compensation increased values fair and common Noncash is with TRANQUILITY fair combined as increased The BXCLXXX costs arising $X.X the approximately also prices in primarily and of grant and stock-based for combined stock-based preparation Investor higher company's from the market the to with to date increased administrative common same for of premiums. also potential XXXX million the of X company's $X.X cancer expenses compared fees million stock. related reduced as Total trials, growth its to of as the costs the costs the same release approximately to compared attributable the commercial corporate $XXX,XXX $XX.X million quarter acceleration additional trials. was the the Research launch General expenses XXXX pancreatic million legal to for to compensation attributable increase increased trial These in related combined to compared increased of third of team period to for by in to to were associated the its prices stock-based BXCLXXX million a approximately of offset expenses of increase, the primarily SERENITY result quarter clinical XXXX. was Professional in XXXX increased partially the to amounts quarter operating of related approximately BTAI's non-cash operating its $X XXXX. related the primarily increased related compared third XXXX. programs and include $XX.X to insurance were The clinical continues in increased compensation personnel period and XXXX, the expenses same of quarter which for expand of Relations the period increased period increase company the for U.S. arising in operations with company's and XXXX. of professional growth BTAI's activities, from research to in due were $X.X total million of costs for values and costs, also non-cash primarily

$XXX.X our September of Review approximately As XX, XXXX, and equivalents million. cash totaled Financial That the third quarter. cash concludes of

Vimal? to for Vimal turn I'd comments. further any like Now, call the back to

Vimal Mehta

Thanks, Richard. to to would We open questions. call Operator? the now like

Operator

first Instructions] the Thank comes with proceed Our with Meacham question of Please you. Bank Geoff of line from your question. America. [Operator

Geoff Meacham

it. lot the Hey, guys. Appreciate a for Thanks question.

the development any kind high think to need the maybe get commercial make this pre-NDA you the maybe of going generic an Then make provides? the what the you. on educate maybe you'd on and a actually points the wanted it backdrop couple of can Vimal what regulatory Maybe options, the you launch totality the or maybe respect Will to about with -- meeting, us just through Thank generic overall for that I wanted as -- and for a to that to how had preparations for to on Just do and any of just to just point updates the availability give or relates physicians efforts level, talk update profile to color have XXX. are whatever you guys just and at the get program.

Vimal Mehta

end. on I and then the on to Geoff. Will commercial will the will cover take pass question, Thanks, it to

Will Kane

Vimal. Thanks, for question. Geoff, thanks Good morning, and the

we pleased that very the are launch. with preparation I'm So making to commercial progress relative for

the we've of previous out ahead ready As narrowing core strategy, talked operations, not but and We help our on staffing to market adding organization well brought to building inform launch a our access. teams. of started so have We're of that We're including when recently we on be research the we'll Marketing. only embarked in market in the etcetera Head commercial on are to comes. way, head we've of time bolus calls, about commercial leadership

leaders we've addition They we teams MSL data providers a add answer previously, and with medical opinion and of about etcetera building as head and key XXX they company, them clinical questions, in field so we've being our and to In intend begin collaborating other the agitation out including their leadership affairs clinicians to and medical begin to Raina first educating the team. of the healthcare with on the be of our to team, date. the MSL talked to able interacting relative quarter to process that deploy and to XXXX team moved key can will

on options. generic to Specific progressing things well way we're are the your and our very marketplace on nicely. So and question

etcetera is received talked but by option clinicians to as not and, feedback acknowledge not care is are countered mentioned, about treatments, concerns, we I facilitate paradigm with like which film, relationship number of thought. viable to of the Yes, limitations to so have of of tolerability a bit generics pharmacists. course, such out treatment patients you as with point use current that profile both done to good actually really that also well. which of they significant of safety should clinicians know, thin what the with But well we've have option. we the So their the inconsistent we they date, clinical treatment drug a those There to The moderate to their and highlighted nature mild the research to consider and as is more we've another agitation. the a injections, The these engage treatment those, oral times they as very the many market opportunity go. treatment XXX as standard they is for of would as than

to I'll Vimal turn regulatory it the question. So over for

Vimal Mehta

the some our submitted FDA So submit on we a meeting, subgroup be are we of the application as XXXX. the is presenting. analyses in to and as stability and Primarily that together clinical to things related is a already of rolling first well that of need to package have regarding the complete submission, put track and to CMC pre-NDA agreed of we'll the which film XX-months some package, be some analysis

NDA So we overall, and track our submit QX for all feel XXXX. a in in we is that are good on all, position to

Geoff Meacham

guys. Thanks, great. Okay,

Operator

Thank you.

proceed Sachs. Our question. next with with coming [ph] from question of line your Greg Please is Goldman the

Unidentified Analyst

the walk Hi, good maybe the morning. be you in you then study us might you Could expect might time. from for if dementia you end to higher for for through Thanks see doses what you going what the you're and up taking testing there? looking XX-dose know

Reina Benabou

the Thank question. you for

and safety the looking profile. we tolerability study of at have looking throughout outcome really clinical primary the So is TRANQUILITY This the the is been trials. what

on end, necessary, will and study proceed this we're review or to dose safety if results to the cohort findings and going quarter, report either another the results giving the at top-line So we the tolerability.

Vimal Mehta

will And decision PK another add the we we at glean can on Reina data blinded if said just and the data Greg, will exposure and to what that about needed, the look dose that data also or I our triangulate data all go from microgram make to efficacy to any cohort. XX information dose the

Unidentified Analyst

Okay, thanks very much.

Operator

Thank you.

next question proceed line comes from of with Our Truist with please your Karnauskas the question. Robyn Securities,

Robyn Karnauskas

and the morning, on Hi, progress. congrats good

two I So questions. have

us. position XX you IP through Thank take? don't months protect patient market? if on market. how for for films deliance, us you us are might Second market that Help How newer congrats we like you to maybe to us really to this variable film take? how generic? can, walk do expect solidify a how the you words, and understand more much that all your patients can, patients what if should diverse in I any for In to model is First, other next additional Can might and IP. each I'd it's outline might many how think XX against you. know you of

Vimal Mehta

this Thanks, take IP in will take parts. question question. handle and the will question Will We'll the Robyn. I second two

in are related and our in agitation. we That's composition Regarding the used issued patent the our very the IP, we that film, excited patent got on it's of first BXCLXXX, to October.

our and strategy So until will that pattern market provide exclusivity XXXX. us first that's

be patients company In that these has at exposure dementia or patients the to dose bipolar addition, which of or in overarching levels been and the the are each trial, experiencing will strategy it's ranges up at look opioids, with we patients whether coming different created. schizophrenia,

are dose in As be agitation requirements the different. in scenario situation, understand you and different acute that chronic can versus will also a subchronic, requirements those

also. levels are patenting we those So exposure

So that's our besides second our part of patent. the film strategy

In continue treatment for we addition, indication, market of a IP particularly to already of different so strategy use agitation maintain as to have -- exclusivity as for around franchise. method the dexmedetomidine, for we patents our filed the is well for there broad related whole

to a setting setting. color almost to pattern for patents, that in being prosecuted I as have it on With the both on Will We well on BXCLXXX. pass and and familiar are that, progress Reina dozen commercial will medical as provide delirium a the

Will Kane

Sure, thanks, and good Thanks Vimal, Robyn. for question. the morning,

be used. and also in wards in and there any for surgical more that the if designed that. of the equally last about And test departments. treatment So when settings three medical treatment average way days. of there experience think we'll think patients films, X We're delirium, X more Reina's potential part number than is from of for majority suffer given Relative and course, talked the significant believe on agitation of films as an opportunity hospitalized associated especially other them episode more the little million delirium as we condition. society, and for it to I year, The five Phase through We every where discussed actually do multiple of in the conducted, significant, not but where is the approved their hospitals. the could our which about way are that delirium view, episode. with is the the to we According to multiple focused this agitation be ICU, emergency can is agitation in the is a commercial learn trial and American consider that for product. XXX you day, trial the it, study no as about a I delirium will to And options

wards to settings, give the I Reina? But informed in an So surgical one maybe two, and be expect trial. which and be to we number. can't be you exact will the in to or could greater by than case emergency ICU department the that it four medical certainly three but the would

Reina Benabou

design. data but based selected which we Will. delirium, culminating in we this also patients. wealth really And together multicenter on from robust putting adaptive Phase doses you, showed even of that Absolutely right, in our classical ascending halibel X data resistant dexmedetomidine paper sequentially is a literature from dose-finding Thank SERENITY a randomized, are the on a the tremendous agitated with efficacy trial,

associated very and So doses that FDA, X a we're and to goal data to be. is dose to with preliminary and that. where tolerable and are move do really decide going efficacy those evaluate in find we're close going And Phase doses to XXX, XXX evaluate trials we're then the our the to PK we're a to scale. XXX some milligrams, is going alignment efficacious data best which then Well, discuss the to and XXX, to with with rat also, this with going also our how another going

Robyn Karnauskas

And just default clear. be and

in trials, or frequently. than certain a you're period able give able maybe time? study, able Because So the at over be agitation would out be film period what withdrawal been than that'd over of give in this point other you've opioid to film more time more read for In except withdrawal. trials more safety, you than a -- opioid dosing of where one to of outside would you not be one different to certain other

Reina Benabou

Exactly, Robyn.

is as said, Will the duration five to between So days. three average of delirium

in hours, zone calming is during what five we're for. other the period dose, days hours. the good that and into that first dose, so a shooting Phase with evaluate why four patient to in a period Then is he trying starting two of then we're have trial in likely optimal X that to the even So This a reduction our take would will the scale XX of right or a patient three doses days. lead will

Vimal Mehta

I add. Robyn, So can

In than we the is determined trial But multiple designed. more film of terms a trial. back be can films day. coming dosing one frequency That's in to can the that question, the how day? of will dose we through dose in your a Yes,

Robyn Karnauskas

question, Last Great. for sorry many. so

for episodic for thinking can the dementia for Because the day. Phase about the is that ability obviously, are dose? something you've when more incorporate again dementia would lasting next one Is pivotal. Would this than question? So that's different would be with past you're step than done than that next explore? you Because since study, have you that for dementia, people also what the your is more one in X, experiences for the

Vimal Mehta

foundation the and repeat study, us study data be in dose, have front TRANQUILITY will what study. dozing will than used. that we we used and referring we through is And the unblinding can once find What are you have be more this one inform can out of the us dosing.

In in somebody we informed understanding a and will they how episodic addition, we agitation it need immediately, treatment be can an get will very used setting. and chronic we setting a it how in use get good when has can

have we into to XXX chronic plan move that the setting. stated We

it be will All alternating? daily informed by used the of be that So TRANQUILITY we'll or can can from it used be the get study. results

that. In catch agitation to Watch developing doses addition, required be for early what very stages are and will Apple we in

card can TRANQUILITY broadly. we make on decisions we that getting So to will that close the treat inform TRANQUILLITY I on rolled will more out think and all be able we then has those and what once of discuss been data are very with the

Robyn Karnauskas

you. thank Great,

Operator

Thank you.

comes the line Yatin question Guggenheim Partners. with with your Our proceed question. from Suneja Please of next

Yatin Suneja

XXX. thank you then taking on have Hey, my a one TRANQUILITY and quick on guys, I question. for

will to XX go you clear happen downtime one the not? you you XX second expansion uptight dose to on trade traction, Then And It's us will the about I'll not microgram for you after you be could whether able go you you ask the if the when on if was down versus expand expanded. or this. additional said could an arm the dose? So dose, go actually down which the micrograms when did then

Vimal Mehta

Yatin. question, Thanks for the

go data, go up FDA, data the so next it's of whether be data scale will goal. think exposure dose that need what of of getting we data to what The microgram PK stage convince to to them That's the I the to to XX we the exposure are the down. inform go we titration a us really to to our in triangulation data will the tolerability inform needs or next what terms we from levels and exposure going take development. be cohort

to cohort. go at this are dose time, on very up point whether So or down both scenarios in well the possible

Yatin Suneja

Okay. MD tumor trials can seems PR the And we the types of to phase talk the different how types like out? were work are study. It data, about going of in expansion XXX, then you on especially those saw maybe different there in Anderson

two conducted that Then to think, tumor you So what going expand, as is, are implementing given this on an makes where sort modification for who and you types you Thank study? are you that MD enriching be as saw decision hypertension? then those you. the Anderson I side, of it PR, relates to safety the

Vimal Mehta

take that to you want Vince, question?

Vince O'Neill

thanks, Good Sure, Vimal. morning.

take the I'll That's answer. one study from the it first. to So easiest prostate

So there cohorts two there is cohort adenocarcinoma Cohort and disease NAPC. X castrate-resistant is X obviously are and

those right. basket So will or trial. a patient Anderson, MD or you're subgroups and sub-segments This absolutely pure you is if pure, the are

look a that if What activity, does seen plot going and fast investigator typically like but think the tend and point. to in activity those tend nicely just the would happen said, enrich patients been quite is happen yes, that's forward. not here. you you to we hard that anticipate that what has of as And we the would types forward will for this a at study having it's enrich, I waterfall going illustrate rule, where seen,

so forward, It's your an happening that absolutely MD would on the going on I sorry, on you're are mitigation, you're but is and the hold trial On Anderson decision-makers point, This the on. study. They safety the right. They right. and You're IND. second absolutely risk IST. anticipate

agents are with data been also target expected, toxicity system. that's activate point I we've seeing So the presented, on we that that innate again, other immune based seen that would on the was the make

cytokines of increase shouldn't some have Again, the So because the seeing they plan essentially it very and doing similar detail within these introduced and similar we down better of profiles. actual safety the mitigation specific similar are are week patients safety something seen detail any occurring profiles or comes very, have to that by currently. monitoring first mystery, within for The tolerability, be the the week really really, follow-up, a to events closer it all granularity. closer first XX

We you will that in give we present as a few months' time.

So question. hopefully that your answers

Vimal Mehta

me cold Vince advanced efficacy Let immunity add at more in a is bit This find are both just the the little of overarching. said to to the activator, systemic. tumors. color trying what And is one signal and innate most hot which we

both it us our plans, and part. studies ongoing to activities, allow the that appropriability will us advanced development gives So the what develop and are agents' more

work done All once be of these that will we two completed. have trials

Yatin Suneja

Thank you.

Operator

Thank you.

with your question Please proceed the Canaccord. Kulkarni of from next question. Sumant Our with line comes

Sumant Kulkarni

actually. have Morning. three I questions

is one The first TRANQUILITY. on

to you So might That's be company to the on you quarter question. be take to an can on do move you the the frame you the able that another to is that drawn be only enough investors conclusion means is decide If what how as how real efficacy might go look highest proceed? help interim at any thoughts that because next to the prior safe in comfortable the dose? fourth to first for be dose able cohort, for to

Vimal Mehta

that you take do to question? Thanks want Sure. Rob,

Robert Risinger

Thanks, Sure. Vimal.

right. much You're pretty

safety so dose, As we when a higher dose-escalating, essentially dose and we level. well-tolerated, on is to and based the are escalate we the next dose safe planned escalate

Vimal Mehta

done, think need consider conclusion on as we'll well. if we see dose, On XX peak down we go be that's that dose, microgram we to the and top-line cohort. are the moving these that levels, the reverse, best that to data exposure way I the But we think after then put announced decisions will either that or another it. we inform Then is dose to and made can

Sumant Kulkarni

Got it. upfront. the two next ask I'll questions Then

for the were you of decks your geriatric move intriguing some and XXX, next can what potential the indication of dementia, on So And if or combo treatment chronic that proceeding, recently, sets you any prostate agitation your not very patient to other are on triple upsides than cognitive there population? is cancer? now data in for priorities comment downsides the

Vimal Mehta

that. try can I

and the We into Frank Rob will then Vince and XXX divide question first two on question question. answer the will and will the take

Frank Yocca

usage say would to cognition, a that it to and I'm deter drug either. guess not that I would Sumant, hazard enhance would with chronic it but regard the cognition, I on your sure think question don't

in population. So a I have use would that to is other of get of course, opposed of some think it And the negative effect. where do used. cognitive are the effect as drugs being neutral benzodiazepines a this This something you

upfront. So that's what thinking I would be

Vimal Mehta

do take the Vince, second you to want question?

Vince O'Neill

Sumant. Good Sure. morning,

some was, initial advisors we question it. about and where have I think our boiling discussions with and the our collaborators we after go thoughts do we this it down? So certainly had some

any public statements made yet. haven't We

on of seeing activity. types will be I we're way. be pursuing indications approach, it in standard track think you in following view course, the the would if you're We've probably a where -- clearly you be this and right tumor we would thinking of the

I cancer data a on development there. a And both needs. that, noting that high-end think more bit information point are a orphans from uvula straightforward [ph] it melanoma orphans of quite there's similarly but we to also need an to is bit approach more medical sarcoma, about a worth probably would treat, extremely is pleomorphic difficult view,

So again, under now. discussion just is this

thinking. that would we'll think the but definitive make subsequently, initial statement be I a

Sumant Kulkarni

you. Got it. Thank

Operator

you. Thank

coming We RX of the proceed your Securities. of comes is on Please from line our questions. proceed question. question H.C. live, Ram, Ram with with with Devani may with which move next Samir Wainwright. your question. proceed Selvaraju to Our question, your next Pleased from you with your a line line is

Samir Devani

taking questions. a everyone. got just Hi, for Thanks I've my couple.

wonder you just one if potentially in can following first just confidence on getting your pre-NDA priority review. The meeting, I your comment

whether second is cancer data the XXX, in comment you've study prostate you just NPC if the on Can on Thanks. group? in group question are on in encouraging The the wondered responses adenocarcinoma they or responses elaborate could seen? some the the just very there. I you

Vimal Mehta

take Thank get XX the priority will full application, drug accepted. once pre-NDA, asking I the case, approximately that the four review. standard question, question. is after FDA If been for the learn first than from we approval Samir. we submit earlier review whether will the days the months you then of In four So could we has

both launch. to ready teams early, get for the commercial be turns it Our do both If to scenarios. be medical out and the approval that commercial are preparing we'll we'll

your For to question Vince? to will pass on related the XXX, Vince. it I

Vince O'Neill

morning. Vimal. thanks, Good Sure,

On side, the and experience with what XB complete just we presented clear, safety activity. of presenting is prostate final or efficacy associated we're a to Phase be really have

reduction efficacy and update the patient. poster, the in minor but well and answer and ad the were we neuroendocrine year. very in half an other XX XX your actually the adenocarcinoma an the with was CRPC were disease question that detailed of nor give valuable PSA scan the of said XX% To half in is and deep were those of XX towards patients portion the and So will some underway end CT we directly, as shrinkage

question. direct to the So answer your that's

Samir Devani

very much. thanks Great,

Operator

questions at Thank no appears have additional this time. you. It we

for the back So I'd like management pass to to closing floor comments.

Vimal Mehta

to everybody thank conclude, us want Before joining for today. I we

significant reach to As milestones trials over upcoming well other and to day questions. have additional any progress, next providing heard the great updates quarter. the made a months. from has forward as you. you you And please several throughout out both on Thank BXCLXXX us and this as BioXcel look call, key ongoing have if results the our Have we BXCLXXX advancing

Operator

time. for Once this may your this and participation today's you again, you webcast. Ladies gentlemen, teleconference lines thank at and concludes your and disconnect we

BioXcel Therapeutics (BTAI) 12 Nov 202020 Q3 Earnings call transcript